Healthcare Sales & Marketing Network News: hypoxia

Searching News Database: hypoxia

HSMN NewsFeed - 29 Oct 2024
Protega Pharmaceuticals Receives FDA Approval for ROXYBOND(TM) (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA

HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2021
Medtronic INVOS(TM) 7100 Cerebral/Somatic Oximetry System receives 510(k) clearance for pediatric indications
Devices Monitoring FDA

HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Aug 2021
KalGene Pharmaceuticals Inc. an Alzheimer's focused company using a next generation engineered drug candidate, has appointed new leadership
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Apr 2021
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Feb 2021
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
Biopharmaceuticals

HSMN NewsFeed - 26 Aug 2020
Akebia Therapeutics Announces First Commercial Launch of VAFSEO(TM) (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan
Biopharmaceuticals Product Launch

HSMN NewsFeed - 29 Jun 2020
Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 May 2020
Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
Biopharmaceuticals

HSMN NewsFeed - 30 Jan 2020
Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership
Biopharmaceuticals Regenerative Medicine Licensing

HSMN NewsFeed - 8 Jul 2019
Skyhawk Therapeutics Announces Addition of World Leading SAB Head & New VP of Oncology Biology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 May 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 May 2019
Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax(R) (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates
Biopharmaceuticals

HSMN NewsFeed - 12 Feb 2019
Edwards Lifesciences Enters Into Agreement To Acquire CASMED
Devices Monitoring Mergers & Acquisitions

HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Oct 2018
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 20 Jul 2018
FDA Grants Approval of TIBSOVO(R), the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Jan 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Aug 2017
Impax Announces Settlement of Contract Litigation on Opana(R) ER (Oxymorphone Hydrochloride) CII Extended-Release Tablets
Biopharmaceuticals Litigation

HSMN NewsFeed - 26 Apr 2017
Inspirion Delivery Sciences Receives FDA Approval for RoxyBond(TM) (oxycodone hydrochloride) tablets CII, the First and Only Immediate Release Opioid Analgesic with Abuse-Deterrent Label Claims
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 14 Mar 2017
Peloton Therapeutics Completes $22.2 Million Private Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Nov 2016
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave(R) (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand
Biopharmaceuticals Distribution

HSMN NewsFeed - 30 Sep 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Sep 2016
Peloton Therapeutics Completes $52.4 Million Private Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 23 May 2016
Egalet Settles Patent Litigations with Purdue Pharma
Biopharmaceuticals Litigation

HSMN NewsFeed - 14 Apr 2016
RefleXion Medical Raises $46 Million Series B Financing Led by KCK Group
Devices Oncology Venture Capital Personnel

HSMN NewsFeed - 21 Mar 2016
Threshold Pharmaceuticals Appoints Stew Kroll as Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Jan 2016
FDA Approves Eisai's Halaven(R) (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Dec 2015
Merck KGaA, Darmstadt, Germany, Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals

HSMN NewsFeed - 24 Sep 2015
Cerulean Appoints David R. Walt, Ph.D. to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Sep 2015
Akebia Therapeutics Announces Additions to its Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jun 2015
XTuit Pharmaceuticals Closes $22 Million Series A Financing to Advance Novel Microenvironmental Modulators for Cancers and Fibrotic Disorders
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 12 May 2015
Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Mar 2015
Selten Pharma, Inc. Receives Orphan Drug Designation From U.S. FDA for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Jan 2015
Cerulean Appoints Vice President, Clinical Operations
Biopharmaceuticals Drug Delivery Oncology Personnel

HSMN NewsFeed - 8 Oct 2014
Masimo Announces CE Mark of the 11th Rainbow(R) Parameter - ORI(TM), Oxygen Reserve Index(TM)
Devices Monitoring Regulatory

HSMN NewsFeed - 6 Aug 2014
Akebia Therapeutics Announces Expansion of Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Jun 2014
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 11 Jun 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Apr 2014
OxySure (OXYS) Announces CE Mark Approval for OxySure Model 615 Portable Emergency Oxygen Device
Devices Regulatory

HSMN NewsFeed - 10 Feb 2014
Two-Year Results From Phase 3 VISTA Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 7 Feb 2014
Covis Pharmaceuticals Announces Its New Expanded Dosage Options of LANOXIN(R) for Cardiac Patients With Mild-to-Moderate Heart Failure
Biopharmaceuticals Cardiology

HSMN NewsFeed - 22 Nov 2013
Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Oct 2013
Akebia Appoints Jason A. Amello as Senior Vice President, Chief Financial Officer and Treasurer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch

HSMN NewsFeed - 28 Aug 2013
Akebia Appoints Renal Industry Veteran John P. Butler as President and CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jun 2013
Dendreon Receives Positive Opinion for PROVENGE(R) in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing

HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Dec 2012
Diffusion Pharmaceuticals Receives FDA Orphan Designation for TSC, a First-in-Class Drug for the Treatment of Metastatic Brain Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Aug 2012
Aerpio Therapeutics Completes $27 Million Series A Financing
Biopharmaceuticals Ophthalmology Venture Capital

HSMN NewsFeed - 16 Aug 2012
Threshold Pharmaceuticals Appoints Laura G. Hansen, Ph.D., Senior Director, Corporate Communications
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Apr 2012
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons

HSMN NewsFeed - 17 Feb 2012
Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Feb 2012
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Nov 2011
Dendreon Announces the Centers for Medicare and Medicaid Services (CMS) Will Now Cover Infusion Costs Associated with the Administration of PROVENGE
Biopharmaceuticals Oncology Reimbursement

HSMN NewsFeed - 2 Nov 2011
Threshold Pharmaceuticals Appoints Nipun Davar as Vice President of Pharmaceutical Development and Manufacturing
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Oct 2011
FDA Approves Combivent(R) Respimat(R) (ipratropium bromide and albuterol) Inhalation Spray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Sep 2011
FibroGen Appoints Michael Martinelli, Ph.D., Vice President of Technical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Aug 2011
NUCYNTA(R) ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Jul 2011
Diffusion Pharmaceuticals Receives FDA Orphan Status for TSC, a First-in-Class Drug for the Treatment of Primary Brain Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 May 2011
Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug
Devices Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 24 May 2011
Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
Devices Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 25 Apr 2011
Threshold Update Since Sudden Death of Its Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Apr 2011
Threshold Announces Unexpected Death of Its Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Oct 2010
OrSense Continuous Non Invasive Hemoglobin Monitoring System Demonstrates Accurate Performance During Hemorrhage Conditions
Devices Monitoring

HSMN NewsFeed - 4 Oct 2010
FDA Issues Complete Response Letter to Johnson & Johnson Pharmaceutical Research & Development Regarding New Drug Application for Tapentadol Extended Release
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Sep 2010
DecImmune Therapeutics Secures $3.2 Million in Development Funding
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 21 Jun 2010
Exelixis Regains Full Rights to Develop and Commercialize XL184
Biopharmaceuticals

HSMN NewsFeed - 1 Jun 2010
Lorus Therapeutics Files Investigational New Drug Application With FDA for Anticancer Drug LOR-253
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 May 2010
Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Mar 2010
OrSense Receives U.S. FDA Approval for NMB-200MP Non-Invasive Oximetry Monitoring System
Devices Monitoring FDA

HSMN NewsFeed - 1 Dec 2009
New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Nov 2009
Duke University Initiates Study of AEOL 10150 to Measure Compound's Ability to Protect Healthy Tissue in Mice Receiving Chemotherapy and Radiation for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
Biopharmaceuticals Oncology Reimbursement

HSMN NewsFeed - 19 Oct 2009
OrSense's NBM-200MP System for Continuous Non-Invasive Hemoglobin and Blood Oximetry Measurements Achieves Superior Performance in Hospital Setting
Devices Monitoring Surgery

HSMN NewsFeed - 15 Oct 2009
Threshold Pharmaceuticals Licenses Glufosfamide to Eleison Pharmaceuticals
Biopharmaceuticals Licensing

HSMN NewsFeed - 28 Sep 2009
MSD Receives Positive CHMP Opinion for 'Januvia(R)' and 'Janumet(R)' as Add-On to Insulin in the European Union
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 4 Aug 2009
Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Jan 2009
Novacea Stockholders Approve Merger With Transcept
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 22 Oct 2008
Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
Biopharmaceuticals

HSMN NewsFeed - 1 Oct 2008
Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 5 Aug 2008
Panacea Pharmaceuticals Announces Appointment of Suzanne Sensabaugh as Vice President, Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Apr 2008
Novacea Receives Notification From Schering-Plough of Termination of Collaboration Agreement
Biopharmaceuticals

HSMN NewsFeed - 28 Feb 2008
Frederick J. Ruegsegger Elected to Novacea's Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Jan 2008
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Dec 2007
Judith A. Hemberger Elected to Novacea's Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Oct 2007
Threshold Pharmaceuticals Announces Corporate Realignment
Biopharmaceuticals

HSMN NewsFeed - 24 Oct 2007
Threshold Announces New President and Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Oct 2007
Novacea Announces Management Changes
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Oct 2007
New Publication Report -- Hyperthermia Plus Cisplatin as a Treatment for Recurrent Cervical Carcinoma for Previously Irradiated Patients
Devices Oncology

HSMN NewsFeed - 20 Sep 2007
Novacea Appoints John P. Walker as CEO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Sep 2007
Pharmacyclics Announces Encouraging Phase 2 Data With Xcytrin(R) in Recurrent Non-Small Cell Lung Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Jul 2007
Panacea Pharmaceuticals Announces the Availability of LC Detect(sm), a Serum-Based Diagnostic Test for Lung Cancer
Diagnostics Oncology

HSMN NewsFeed - 21 Jun 2007
Varian Medical Systems Names C. Clifton Ling as Director of Advanced Clinical Research
Devices Oncology Personnel

HSMN NewsFeed - 6 Jun 2007
Clinical Results From EntreMed's Panzem(R) NCD and Taxol(R) Breast Cancer Study Presented at ASCO
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine(R) (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2007
Panacea Pharmaceuticals Announces the Availability of PC Detect(sm) for Prostate Cancer Screening
Diagnostics Oncology

HSMN NewsFeed - 30 May 2007
Novacea and Schering-Plough Enter Into Worldwide Development and Commercialization Agreement for Asentar, a Novel Treatment for Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2007
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 May 2007
Vion Announces Suspension of Phase III Trial in Relapsed AML
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Apr 2007
Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 16 Apr 2007
Integra LifeSciences Announces New Proposed Tracking Codes for Intracranial Monitoring
Devices Monitoring Reimbursement Neurosurgery

HSMN NewsFeed - 11 Apr 2007
Dr. James Tanguay Joins Vion Pharmaceuticals' Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Mar 2007
MGI PHARMA Announces Positive Results from a Pivotal Phase 3 Study of Aquavan(R) Injection in Patients Undergoing Bronchoscopy
Biopharmaceuticals

HSMN NewsFeed - 16 Mar 2007
Diffusion Pharmaceuticals Initiates Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC)
Biopharmaceuticals

HSMN NewsFeed - 7 Feb 2007
Proacta Inc Completes $35M Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 6 Feb 2007
Alliance Pharmaceutical Corp. Completes the Manufacture of Oxygent (TM) for Clinical Trials
Biopharmaceuticals

HSMN NewsFeed - 10 Jan 2007
Panacea Pharmaceuticals Appoints Pamela Harris, MD, Vice President Medical and Clinical Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Jan 2007
Phase II clinical trial of Biomira's PX-12 in patients with advanced pancreatic cancer now open for patient enrollment
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Dec 2006
CAS Medical Systems, Inc. Launches FORE-SIGHT(TM) Cerebral Oximeter at the PostGraduate Assembly for Anesthesiology
Devices Monitoring

HSMN NewsFeed - 13 Dec 2006
Vion Pharmaceuticals Enters Into Manufacturing Agreement for Cloretazine(R) (VNP40101M) With Ben Venue Laboratories
Biopharmaceuticals

HSMN NewsFeed - 7 Dec 2006
Novacea Announces Resignation of Brad Goodwin as CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Nov 2006
Vion Pharmaceuticals Reaches Midpoint of Patient Accrual to Cloretazine(R) (VNP40101M) Phase III Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Nov 2006
Alliance Pharmaceutical Corp. Provides Clinical Study Update
Biopharmaceuticals Surgery

HSMN NewsFeed - 1 Nov 2006
Novacea Initiates Phase 1/2 Trial of AQ4N in Glioblastoma Multiforme
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Oct 2006
BSD Medical Presents Cutting-Edge Cancer Treatment Systems at New York Oncology Congress
Devices Oncology

HSMN NewsFeed - 31 Oct 2006
Biomira Announces Acquisition of ProlX Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 26 Oct 2006
Vion Pharmaceuticals Presents Initial Data From a Phase II Trial of Cloretazine(R) (VNP40101M) in Patients With Relapsed or Refractory Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Oct 2006
Covalon Announces Completed Acquisition of Perfusion Therapeutics' Gene Therapy Technology
Devices Mergers & Acquisitions

HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Oct 2006
EpiCept Announces IND Filing of Novel Compound with Potent Apoptotic and Tumor Selective Vascular Disruptive Activity for Treatment of Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Sep 2006
Panacea Pharmaceuticals Announces Appointments of Christine L. Brauer, Ph.D. as Vice President, Regulatory Affairs; and Jefferey Jones, M.S., as Director of Quality
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Sep 2006
FibroGen Appoints Melissa L. Grigorieff, Vice President of Marketing
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Jul 2006
Aileen Ryan Joins Vion Pharmaceuticals' Senior Management Team
Biopharmaceuticals

HSMN NewsFeed - 28 Jun 2006
EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Jun 2006
Panacea Pharmaceuticals Announces Appointment of Stephen N. Keith, MD, MSPH as President and Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals

HSMN NewsFeed - 31 May 2006
Vion Pharmaceuticals Provides Update for Clinical and Preclinical Programs
Biopharmaceuticals

HSMN NewsFeed - 24 May 2006
Vion Initiates Pivotal Phase II Trial of Single Agent Cloretazine(R) in Elderly Patients with De Novo Poor-Risk Acute Myelogenous Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 May 2006
John Gutheil, M.D., Joins Proacta as Chief Medical Officer and Senior Vice President of Clinical Affairs
Biopharmaceuticals Personnel

Return to NewsFeed

Additional items found! 102

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 102 additional stories matching:
hypoxia
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.